Needle-free jet injection devices can and should play a major role in solving the problems of needle-stick injuries and needle phobia in the United States. However, the needle-free jet injector industry is struggling to overcome significant obstacles in this country and abroad before these devices become widely accepted and used for administering drugs and especially vaccines.
Kalorama feels that the line between drug delivery and drug substance will continue to become more elusive in the near future as shown in the analysis, as researchers work to improve drug properties through drug design and molecular modeling. Consequently, in the next decade, drug delivery technologies will be a focal point of competition within the pharmaceutical industry.
The success of specific drugs will be tied to innovative delivery techniques, which will enable the targeting that will exploit the clinical properties of a new generation of drugs.
The implantable/injectable drug delivery market is growing rapidly. The development of better delivery systems in conjunction with the discovery of novel pharmacological compounds will lead to significant improvements in drug delivery. The market for implantable/injectable drug delivery is a dynamic market that is expected to increase during the forecast period. There will likely be significant increases in revenues of needle-free delivery of injectable medications especially in the vaccine arena.
Most needle-free jet injectors use metal springs, compressed air, or CO2 gas to power the injection. The device's nozzle is held against the patient's skin and once activated, the device injects a fine stream of the vaccine or drug at a high pressure into the skin. The most common orifice size is 0.127 mm, whereas that of a 25-gauge needle is 1 mm.
Kalorama information projects growth in these systems in its new report: